tradingkey.logo

Iovance Biotherapeutics Inc <IOVA.OQ> expected to post a loss of 24 cents a share - Earnings Preview

ReutersMay 6, 2025 9:30 PM
  • Iovance Biotherapeutics Inc IOVA.OQ IOVA.O is expected to show a rise in quarterly revenue when it reports results on May 8 for the period ending March 31 2025

  • The San Carlos California-based company is expected to report a 11,327.2% increase in revenue to $81.705 million from $715 thousand a year ago, according to the mean estimate from 11 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Iovance Biotherapeutics Inc is for a loss of 24 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 0.3% in the last three months. ​

  • Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $18.00​, above​ its last closing price of $3.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.27

-0.27

-0.26

Beat

2.7

Sep. 30 2024

-0.31

-0.30

-0.28

Beat

6.4

Jun. 30 2024

-0.35

-0.35

-0.34

Beat

3.8​

Mar. 31 2024

-0.42

-0.42

-0.42

Met

0.6

​​Dec. 31 2023

-0.43

-0.43

-0.45

Missed

-4.3

Sep. 30 2023

-0.46

-0.45

-0.46

Missed

-1.3​

Jun. 30 2023

-0.82

-0.80

-0.47

Beat

41

Mar. 31 2023

-0.77

-0.74

-0.50

Beat

32.9

This summary was machine generated May 6 at 21:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI